Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ODP2301
- Development stage
- Preclinical
- Lead developer
- Oncocross
01
Overview
ODP2301 is an early-stage preclinical oncology drug candidate being developed by Oncocross (including its subsidiary Oncocross Australia). The compound was identified using the company's proprietary RAPTOR AI™ platform, an AI-driven drug discovery engine that analyzes transcriptomic data to identify potential therapeutic candidates. Currently in the in silico or early preclinical phase, ODP2301 is intended for the treatment of oncology-related diseases. Specific technical details regarding its biological target, molecular modality (such as small molecule or biologic), and exact mechanism of action have not yet been publicly disclosed by the developer.
Beyond the preview
Go deeper on ODP2301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ODP2301.